Hubei Goto Biopharm Co.,Ltd. (SHE:300966)

China flag China · Delayed Price · Currency is CNY
26.03
+1.02 (4.08%)
Apr 30, 2026, 12:54 PM CST
68.70%
Market Cap 2.88B
Revenue (ttm) 606.18M
Net Income (ttm) -73.36M
Shares Out 115.08M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,441,449
Average Volume 3,401,431
Open 21.49
Previous Close 25.01
Day's Range 21.49 - 26.03
52-Week Range 15.18 - 29.77
Beta 0.25
RSI 76.79
Earnings Date Apr 29, 2026

About Hubei Goto Biopharm

Hubei Goto Biopharm Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid drug raw materials in China and internationally. It offers starting materials, intermediates, and other pharmaceutical raw materials. The company was founded in 2006 and is based in Xiangyang, China. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 817
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300966
Full Company Profile

Financial Performance

In 2025, Hubei Goto Biopharm's revenue was 606.18 million, an increase of 12.97% compared to the previous year's 536.60 million. Losses were -73.36 million, 165.9% more than in 2024.

Financial Statements

News

There is no news available yet.